RNA-sequencing based gene variants observed in patients with hyperlipidemia and premature coronary heart disease: A preliminary study
Issued Date
2026-03-01
Resource Type
eISSN
24055808
Scopus ID
2-s2.0-105028486692
Journal Title
Biochemistry and Biophysics Reports
Volume
45
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biochemistry and Biophysics Reports Vol.45 (2026)
Suggested Citation
Dechkhajorn W., Prasongsukarn K., Benjathummarak S., Topanurak S., Maneerat Y. RNA-sequencing based gene variants observed in patients with hyperlipidemia and premature coronary heart disease: A preliminary study. Biochemistry and Biophysics Reports Vol.45 (2026). doi:10.1016/j.bbrep.2026.102466 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/114786
Title
RNA-sequencing based gene variants observed in patients with hyperlipidemia and premature coronary heart disease: A preliminary study
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Familial hypercholesterolemia (FH) is a genetic disorder characterized by markedly elevated low-density lipoprotein (LDL) cholesterol levels, which primarily progresses to premature or familial coronary heart disease (FH-CHD). This cross-sectional study included healthy controls (N) and patients with hyperlipidemia (H), FH, CHD, and FH-CHD. We attempted to explore gene variants shared in H, FH and FH-CHD using next-generation sequencing tool. The RNA-seq transcriptome profiling from the whole peripheral blood (n = 3/group) were analyzed. The results revealed 15 intersected gene variants between the H/FH and FH-CHD groups. Aligning and mapping on the coding regions showed significant high-impact variants in 6 of the 15 genes including MAFG , AKAP1 , TLR5 , CHUK, EMC10, and PLRG1. The significant high-impact variations included frameshift variants in CHUK and PLRG, stop-gain variation in TLR5 at the last intron, stop-lost variation in EMC10, and splice-acceptor and donor variants in MAFG and AKAP1 , respectively. Pathogenicity scoring (ACMG Criteria) interpreted that these variation effects are predicted to lose the gene functions. Based on reference databases without any validation, these gene variations are probably linked to atherogenesis and CHD development. Conclusively, our exploratory observed that MAFG , AKAP1 , TLR5 , CHUK, EMC10, and PLRG1 variants had higher impacts and might be related to premature CHD development. Further classification and functional validation of these genetic variations should be considered for the feasibility of using these gene variants as contributory predictors of the FH-CHD risk in hyperlipidemia patients.